In patients with CRC who had not received prior KRAS G12C inhibitor treatment, single-agent divarasib achieved a response rate of 35.9%11, while the combination of divarasib and cetuximab achieved a response rate of 62.5%. The gene discussed is KRAS; the disease is colorectal carcinoma.